Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie III fazy oceniające bezpieczeństwo i skuteczność pitolisantu u dorosłych pacjentów z idiopatyczną nadmierną sennością

24 września 2026 zaktualizowane przez: Harmony Biosciences Management, Inc.

Podwójnie ślepe, kontrolowane placebo, randomizowane badanie z odstawieniem w celu oceny bezpieczeństwa i skuteczności pitolisantu u dorosłych pacjentów z idiopatyczną hipersomnią

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in participants with idiopathic hypersomnia (IH) age ≥18 years.

Key secondary objectives of this study are to assess the impact of pitolisant on:

  • Overall symptoms of IH
  • Participant impression of overall change in their symptoms of IH
  • Investigator assessment of overall disease severity of IH

Other secondary objectives of this study are to assess the impact of pitolisant in participants with IH on:

  • Participant impression of overall severity of their EDS
  • Functional status and activities of daily living
  • Sleep-related impairment
  • Sleep inertia
  • Cognitive function

Przegląd badań

Szczegółowy opis

This is a double-blind, placebo-controlled, randomized withdrawal study in adult participants (ages ≥18 years) with IH. The study will consist of a Screening Period (up to 28 days), an 8-week Open-Label Phase, and a 4-week Double-Blind Randomized Withdrawal Phase.

The Open-Label Phase of the study will be 8 weeks, which includes a 6-week Dose Optimization Period and a 2-week Stable Dose Period. In the Dose Optimization Period, all participants will be titrated to their optimal dose of open-label pitolisant (17.8 milligrams [mg] or 35.6 mg) based on Investigator assessment of tolerability and efficacy. The 3-week titration period will be followed by 3 weeks of flexible dosing (weeks 4-6) during which participants will continue to receive their optimal dose of 17.8 mg or 35.6 mg open-label pitolisant. Participants taking a strong cytochrome P450 2D6 (CYP2D6) inhibitor will be allowed in the study; however, for these participants, the maximum permitted daily dose of pitolisant will be 17.8 mg. Following completion of the 6-week Dose Optimization Period, participants will enter the 2-week Stable Dose Period. During this period, participants will remain at their optimal dose (the same dose they were taking at the end of the Dose Optimization Period [17.8 mg or 35.6 mg]) of open-label pitolisant for 2 weeks; dose adjustments are not allowed during the Stable Dose Period. At the end of the Stable Dose Period, participants will be defined as responders or non-responders. Responders will be randomized in a 1:1 ratio to receive blinded study drug (pitolisant or matching placebo) in the Double-Blind Randomized Withdrawal Phase of the study. Non-responders will not be randomized to treatment in the Double-Blind Randomized Withdrawal Phase and will complete two safety follow-up telephone contacts (TCs) at 15 (±3) days and 30 (+3) days after their final dose of open-label pitolisant.

During the Double-Blind Randomized Withdrawal Phase, participants (approximately 64 participants per treatment group) will receive blinded study drug either at the same dose they were taking in the Stable Dose Period (17.8 mg or 35.6 mg pitolisant) or matching placebo. The duration of the Double-Blind Randomized Withdrawal Phase will be 4 weeks (weeks 9-12); dose adjustments are not permitted during this phase of the study. After completion of the Double-Blind Randomized Withdrawal Phase (End-of Treatment Visit is on Day 84, the last day of blinded treatment), participants will complete two safety follow-up TCs with the site at 15 (±3) days and 30 (+3) days after their final dose of blinded study drug, which will include assessment for adverse events and concomitant medication use; alternatively, participants will have the opportunity to enroll in a long-term, open-label safety study under a separate protocol. Participants who opt to enroll into the long-term, open-label study will not complete the 15-day and 30-day follow-up TCs.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

214

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Arizona
      • Peoria, Arizona, Stany Zjednoczone, 85381
        • Phoenix Medical Group
      • Scottsdale, Arizona, Stany Zjednoczone, 85259
        • Mayo Clinic
    • California
      • Los Angeles, California, Stany Zjednoczone, 90095
        • University of California- Los Angeles
      • Los Angeles, California, Stany Zjednoczone, 90048
        • Cedars-Sinai Medical Towers
      • San Ramon, California, Stany Zjednoczone, 94583
        • Sleep Medicine Specialists of California
      • Santa Ana, California, Stany Zjednoczone, 92705
        • SDS Clinical Trials Inc.
      • Santa Monica, California, Stany Zjednoczone, 90404
        • Santa Monica Clinical Trials
    • Colorado
      • Boulder, Colorado, Stany Zjednoczone, 80301
        • Alpine Clinical Research Center
    • Connecticut
      • Norwalk, Connecticut, Stany Zjednoczone, 06850
        • Norwalk Hospital Sleep Center
    • Florida
      • Brandon, Florida, Stany Zjednoczone, 33511
        • Meris Clinical Research
      • Clearwater, Florida, Stany Zjednoczone, 33765
        • St. Francis Medical Institute
      • Miami, Florida, Stany Zjednoczone, 33126
        • Sleep Medicine Specialists of South Florida, PA
      • St. Petersburg, Florida, Stany Zjednoczone, 33763
        • Pasadena Center For Medical Research, LLC
      • Winter Park, Florida, Stany Zjednoczone, 32789
        • Florida Pediatric Research Institute
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30328
        • Neurotrials Research Inc.
      • Gainesville, Georgia, Stany Zjednoczone, 30501
        • The Neurological Center of North GA
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Northwestern University
      • Glenview, Illinois, Stany Zjednoczone, 60026
        • NorthShore Uni HealthSys-Glenbrook Hospital
      • Peoria, Illinois, Stany Zjednoczone, 61637
        • OSF HealthCare Saint Francis Medical Center
    • Maryland
      • Chevy Chase, Maryland, Stany Zjednoczone, 20815
        • Helene A. Emsellem MD PC
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02115
        • Boston Children's Hospital
      • Newton, Massachusetts, Stany Zjednoczone, 02459
        • Neurocare, INC
    • Michigan
      • Novi, Michigan, Stany Zjednoczone, 48377
        • Henry Ford Health System
      • Portage, Michigan, Stany Zjednoczone, 49024
        • Bronson Sleep Health
      • Sterling Heights, Michigan, Stany Zjednoczone, 48314
        • Clinical Neurophysiology Services
    • Minnesota
      • Edina, Minnesota, Stany Zjednoczone, 55125
        • Minnesota Lung Center
      • Woodbury, Minnesota, Stany Zjednoczone, 55125
        • Minnesota Lung Center
    • Missouri
      • Chesterfield, Missouri, Stany Zjednoczone, 63017
        • St. Luke's Sleep Medicine and Research Center
      • St Louis, Missouri, Stany Zjednoczone, 63123
        • Clayton Sleep Institute
    • Nebraska
      • North Platte, Nebraska, Stany Zjednoczone, 69101
        • Great Plains Health
    • New Jersey
      • West Long Branch, New Jersey, Stany Zjednoczone, 07764
        • Neurology Specialists of Monmouth County, PA
    • New York
      • New Hyde Park, New York, Stany Zjednoczone, 11042
        • Northwell Health
    • North Carolina
      • Denver, North Carolina, Stany Zjednoczone, 28037
        • Research Carolina Elite LLC
      • Durham, North Carolina, Stany Zjednoczone, 27705
        • Duke University School of Medicine
      • Gastonia, North Carolina, Stany Zjednoczone, 28054
        • Clinical Research of Gastonia
      • Huntersville, North Carolina, Stany Zjednoczone, 28078
        • ARSM Research
    • Ohio
      • Canton, Ohio, Stany Zjednoczone, 44718
        • NeuroScience Research Center, LLC
      • Cincinnati, Ohio, Stany Zjednoczone, 45245
        • Intrepid Research, LLC
      • Cleveland, Ohio, Stany Zjednoczone, 44195
        • Cleveland Clinic
      • Cleveland, Ohio, Stany Zjednoczone, 44106
        • Rainbow Babies Children's Hospital
      • Dublin, Ohio, Stany Zjednoczone, 43017
        • Ohio Sleep Medicine and Neuroscience Institute
      • Middleburg, Ohio, Stany Zjednoczone, 44130
        • North Star Medical Research
    • Oklahoma
      • Ardmore, Oklahoma, Stany Zjednoczone, 73401
        • CardioVoyage
    • Pennsylvania
      • Paoli, Pennsylvania, Stany Zjednoczone, 19301
        • Brian Abaluck, LLC
      • Willow Grove, Pennsylvania, Stany Zjednoczone, 19090
        • Abington Neurological Associates
      • Wyomissing, Pennsylvania, Stany Zjednoczone, 19610
        • Respiratory Specialists
    • South Carolina
      • Charleston, South Carolina, Stany Zjednoczone, 29425
        • Medical University of South Carolina- Institute of Psychiatry
      • Columbia, South Carolina, Stany Zjednoczone, 29201
        • Bogan Sleep Consultants
      • North Charleston, South Carolina, Stany Zjednoczone, 29406
        • Lowcountry Lung Critical Care
    • Tennessee
      • Chattanooga, Tennessee, Stany Zjednoczone, 37421
        • Advanced Center for Sleep Disorders
      • Cordova, Tennessee, Stany Zjednoczone, 38018
        • Neurology Clinic, P.C.
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78731
        • FutureSearch Trials of Neurology LP
      • Round Rock, Texas, Stany Zjednoczone, 78681
        • Central Texas Neurology Consultants, PA
      • Sugar Land, Texas, Stany Zjednoczone, 77478
        • Comprehensive Sleep Medicine Associates
      • Tomball, Texas, Stany Zjednoczone, 77375
        • Northwest Houston Neurology and Sleep
    • Virginia
      • Norfolk, Virginia, Stany Zjednoczone, 23507
        • Children's Hospital of the King's Daughter
    • West Virginia
      • Morgantown, West Virginia, Stany Zjednoczone, 26506
        • West Virginia University - Department of Neurology
    • Wisconsin
      • Madison, Wisconsin, Stany Zjednoczone, 53719
        • University of Wisconsin-Madison

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Is able to provide voluntary, written informed consent.

  2. Has a current diagnosis of IH per International Classification of Sleep Disorders Third Edition criteria.

  3. Male or female participant age ≥18 years at the time of Screening.

  4. Has an Epworth Sleepiness Scale score of ≥12 at Screening and at Baseline (Visit 2).

  5. Has a Patient Global Impression of Severity score of moderate, severe, or very severe at Screening and at Baseline (Visit 2).

  6. For participants being treated for obstructive sleep apnea (OSA) or other hypoventilatory conditions, participants must be compliant as demonstrated by bilevel positive airway pressure/continuous positive airway pressure (BiPAP/CPAP) therapy with 30 days of data showing ≥4 hours of BiPAP/CPAP therapy per night for ≥70% of nights. If not on BiPAP/CPAP therapy, participants being treated for OSA must be compliant as determined by the Investigator with their medical device or oral appliance. Data must be from within 90 days prior to the Screening visit. Participants must agree to maintain compliance with their treatment for OSA throughout the duration of the study.

  7. If on a treatment that could affect daytime sleepiness (including but not limited to oxybates, stimulants, modafinil, and armodafinil):

    1. Must be on a stable dose for at least 2 months prior to Screening and agree to continue the stable dose for the duration of the study.
    2. If not on a stable dose for 2 months prior to Screening, washout for 5 half-lives or 14 days, whichever is longer, prior to Day 1 and agree to remain off these treatments until completion of the study.
  8. A participant who is a female of child-bearing potential must have a negative serum pregnancy test at the Screening Visit and negative urine pregnancy test at the Baseline Visit (Visit 2) and at the end of the Stable Dose Period (Visit 4) and agree to remain abstinent or use an effective method of non-hormonal contraception to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug.

  9. Must have a negative result on urine drug screen at the Screening Visit, Baseline Visit (Visit 2) and at the end of the Stable Dose Period (Visit 4), except for medications that are prescribed by a healthcare provider for medical conditions.

  10. In the opinion of the Investigator, the participant is capable of understanding and complying with the protocol and administration of oral study drug.

Exclusion Criteria:

  1. Has hypersomnia due to another medical disorder (for example, narcolepsy).
  2. Has an Apnea Hypopnea Index of ≥10 as determined by the most recent sleep study or BiPAP/CPAP device readout.
  3. Has a clinically significant hypoventilatory condition as determined by the Investigator.
  4. Has a primary diagnosis of a psychiatric illness that is not well controlled.
  5. Participants taking antidepressants who have not been on a stable dose of their antidepressant for at least 12 weeks prior to Screening; participants on a stable dose of their antidepressant for at least 12 weeks prior to Screening must agree to continue their stable dose for the duration of the study.
  6. Experiences a mean of <6 hours of sleep per night based on sleep diary during Screening (participants need to record at least 7 nights within a 10-day period in their sleep diary within 14-days prior to the Baseline Visit [Visit 2]).
  7. Consistently consumes >600 mg of caffeine per day and is unable/unwilling to reduce caffeine intake to ≤600 mg per day for the duration of the study.
  8. Does not agree to discontinue any prohibited medication or substance listed in the protocol.
  9. Is currently or has previously used pitolisant.
  10. Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 21 days after final dose of study drug.
  11. Participation in an interventional research study involving another investigational medication, device, or behavioral treatment within 28 days or within 5 half-lives of the investigational medication (whichever is longer) prior to Screening.
  12. Has a diagnosis of end-stage renal disease (estimated glomerular filtration rate [eGFR] of <15 milliliters [mL]/minute/1.73 square meter [m^2]) or severe hepatic impairment (Child-Pugh C).
  13. Has a diagnosis of moderate or severe renal impairment (eGFR ≥15 to ≤59 mL/minute/1.73 m^2) or moderate hepatic impairment (Child-Pugh B) at Screening or at any time during the study.
  14. Has a history of long corrected QT interval syndrome or corrected QT interval using Fridericia's formula (QTcF) >450 milliseconds (msec) for males or >470 msec for females (QTcF = QT / 3√ RR) at Screening.
  15. Is receiving and is unable to discontinue a medication known to prolong the QT interval.
  16. Is receiving a concomitant medication that is known to be a strong cytochrome P450 3A4 inducer, or a centrally acting histamine 1 receptor antagonist; participants who undergo a washout of these medications of at least 5 half-lives or one week (whichever is longer) may be enrolled in the study. Use of strong CYP2D6 inhibitors is allowed; however, for these participants the maximum permitted daily dose of pitolisant is 17.8 mg.
  17. Is a known CYP2D6 poor metabolizer.
  18. Has abnormal laboratory values at Screening that are clinically significant as determined by the Investigator.
  19. Has initiated any new or change in allied health therapies or interventions that can interfere with the study outcomes within 28 days prior to Screening and at any time during the study, based on the Investigator's judgment.
  20. Has a current or recent (within 1 year) history of a substance use disorder or dependence disorder, including alcohol, tobacco, and caffeine use disorders as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.
  21. Has planned surgery during the study.
  22. Has a significant risk of committing suicide or suicidality based on history; routine psychiatric examination; Investigator's judgment; or an answer of "yes" on any question other than questions 1 to 3 (for the previous month) or "yes" on any question in the suicidal behavior section (for the past year) of the Columbia-Suicide Severity Scale, Baseline/Screening.
  23. Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to an unstable or uncontrolled medical condition or one that might interfere with the conduct of the study, confound interpretation of study results, pose a health risk to the participant, or compromise the integrity of the study. This exclusion criterion applies not only to entry into the study, but also to continuation in the study, should such an unstable, uncontrolled, or serious medical condition arise.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Double-blind Pitolisant

Double-blind pitolisant administered once daily in the morning upon wakening for 4 weeks during the Double-Blind Randomized Withdrawal Phase

Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.

Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.

Komparator placebo: Double-blind Placebo

Matching placebo administered once daily in the morning upon wakening for 4 weeks during the Double-Blind Randomized Withdrawal Phase

Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.

Eksperymentalny: Open-label Pitolisant

Open-label pitolisant administered once daily in the morning upon wakening for 8 weeks during the Open-Label Phase

Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 millimeters (mm) in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.

Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Epworth Sleepiness Scale (ESS) Score From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher point totals represent more severe daytime sleepiness.

Week 8 to Week 12

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in Idiopathic Hypersomnia Severity Scale (IHSS) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms.

Week 8 to Week 12
Proportion of Participants Who Worsened on the Patient Global Impression of Change for Idiopathic Hypersomnia (PGI-C [IH]) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

The Patient Global Impression of Change for Idiopathic Hypersomnia (PGI-C [IH]) is a single-item questionnaire that assesses a participant's overall impression of the change in their symptoms of IH. The scale asks participants to rate their overall impression of the change in their symptoms of IH since a specific timepoint on a 5-point verbal rating scale ranging from "much better" to "much worse."

Week 8 to Week 12
Change in Clinical Global Impression of Severity for IH (CGI-S [IH]) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

The CGI-S (IH) is an investigator-rated assessment. It uses a single-item, 5-point Likert-type rating scale that ranges from: none (1); mild (2); moderate (3); severe (4); very severe (5). An assessment of less severe symptoms represents an improvement in the investigator's perception of the participant's overall clinical status related to idiopathic hypersomnia and is reflected by a decrease in score.

Week 8 to Week 12
Change in Patient Global Impression of Severity Scale for Excessive Daytime Sleepiness (PGI-S [EDS]) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

The Patient Global Impression of Severity for Excessive Daytime Sleepiness (PGI-S [EDS]) asks participants to rate their overall impression of the severity of their EDS over the past 7 days on a 5-point verbal rating scale ranging from "none" to "very severe". Scores are: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe.

Week 8 to Week 12
Change in Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

The Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) consists of 10 items assessing the impact of sleepiness on daily functioning across 5 domains: vigilance, general productivity, social outcomes, intimacy, and activity level. Each item is rated on a scale of 0 (activity not performed for other reasons), 1 (extreme difficulty), 2 (moderate difficulty), 3 (a little difficulty), and 4 (no difficulty). The FOSQ-10 total score is calculated by multiplying the mean of the subscale scores by five, with final scores ranging from 5-20. Higher scores correspond to less impairment/symptomatic severity.

Week 8 to Week 12
Change in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Short Form 8a (PROMIS-SRI SF 8a) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

The PROMIS-SRI SF 8a is a self-report measure that includes 8 questions designed to assess a participant's perceptions of their waking alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness over the past week. Responses are rated using a 5-point scale, with responses ranging from: 1=not at all; 2=a little bit; 3=somewhat; 4=quite a bit; 5=very much, with average scores ranging from 8 to 40. Raw scores are converted to a T-score using the conversion table from the PROMIS-SRI Scoring Manual. Raw score ranges from 8 to 40; T-score ranges from 30 to 80.1. Higher scores represent greater impairment.

Week 8 to Week 12
Change in Sleep Inertia Questionnaire (SIQ) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

The Sleep Inertia Questionnaire (SIQ) consists of 21 questions that assess sleep inertia. Each question is rated on a scale of 1 to 5, where: 1=not at all; 2=a little; 3=somewhat; 4=often; 5=all the time. Total scores range from 21 to 105. Higher scores represent greater sleep inertia.

Week 8 to Week 12
Change in Cogstate One Back Test (ONB) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

Cognition was assessed using the Cogstate Computerized Cognitive Battery tests. The cognitive domain of working memory was assessed specifically with the One Back Test (ONB), which measures the speed of the participant's response. Results are reported as the mean of the common logarithm (log 10) transformed reaction time (in milliseconds [msec]) for correct responses. A decrease in score represents an increase in working memory performance.

Week 8 to Week 12
Change in Cogstate Identification Test (IDN) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

Cognition was assessed using the Cogstate Computerized Cognitive Battery tests. The cognitive domain of visual attention was assessed using the Identification Test (IDN). Results reported as the mean of the log 10 transformed reaction time for correct responses. A decrease in score represents an increase in visual attention performance.

Week 8 to Week 12
Change in Cogstate Detection Test (DET) From Week 8 to Week 12
Ramy czasowe: Week 8 to Week 12

Cognition was assessed using the Cogstate Computerized Cognitive Battery tests. The cognitive domain of psychomotor function was assessed specifically using the Detection Test (DET). The test measures the speed of the participant's response. Results reported as the mean of the log 10 transformed reaction time (msec) for the correct responses. A decrease in score represents an increase in psychomotor function performance.

Week 8 to Week 12

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Change in ESS Score From Week 1 to Week 8
Ramy czasowe: Week 1 to Week 8

The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher point totals represent more severe daytime sleepiness.

Week 1 to Week 8
Change in Idiopathic Hypersomnia Severity Scale (IHSS) Score From Week 1 to Week 8
Ramy czasowe: Week 1 to Week 8

The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms.

Week 1 to Week 8

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

25 maja 2022

Zakończenie podstawowe (Rzeczywisty)

8 września 2023

Ukończenie studiów (Rzeczywisty)

8 września 2023

Daty rejestracji na studia

Pierwszy przesłany

1 grudnia 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

1 grudnia 2021

Pierwszy wysłany (Rzeczywisty)

14 grudnia 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

25 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

24 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj